Solvonis chief scientist to speak on psychedelic therapy at major US addiction research forum

Solvonis Therapeutics' chief scientific officer, Professor David Nutt, will speak at the 14th Joint Meeting of US federal addiction research bodies on May 6, 2026. He is the sole external speaker at this NIH-coordinated event, discussing psychedelic therapy for addictions, which aligns with Solvonis' drug development programs for alcohol and stimulant use disorders. This highlights the company's relevance in cutting-edge addiction treatment research, although it does not imply official endorsement by US agencies.